Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 1/7/2020
SIETES contiene 93059 citas

 
 
 1 a 20 de 287 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
2. Cita con resumen
Kunchok A, Aksamit Jr AJ, Davis III JM, Kantarci OH, Keegan M, Pittock SJ, Weinshenker BG, McKeon A. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurology 2020:18 de mayo. [Ref.ID 103656]
3. Cita con resumen
Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to infliximab during pregnancy: post-marketing experience. Drug Saf 2020;43:febrero. [Ref.ID 103539]
4.Enlace a cita original Cita con resumen
Yong HY, McKay KA, Daley CGJ, Tremlett H. Drug exposure and the risk of multiple sclerosis: a systematic review. Pharmacoepidemiol Drug Saf 2018;27:febrero. [Ref.ID 102630]
5.Enlace a cita original Cita con resumen
Desai RJ, Bateman BT, Huybrechts KF, Patorno E, Hernández-Díaz S, Park Y, Dejene SZ, Cohen J, Mogun H, Kim SC. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ 2017;356:j895. [Ref.ID 101510]
6. Cita con resumen
Anónimo. Inflectra - An infliximab biosimilar. Med Lett Drugs Ther 2017;59:23-5. [Ref.ID 101422]
7. Cita con resumen
Alijotas-Reig J, Esteve-Valverde E. Embarazo y enfermedades autoinmunitarias. Med Clin (Barc) 2017;148:161-3. [Ref.ID 101400]
8. Cita con resumen
Smolen JS, Burmester G-R, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Gervitz L, Ionescu L, Peterson L, Fleischmann R. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 2016;388:2763-74. [Ref.ID 101029]
9. Cita con resumen
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao L-L, MIao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel J-F, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Dieleman LA, Katz S, Rutgeerts P, for the UNITI-IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2016;375:1946-60. [Ref.ID 100991]
10. Cita con resumen
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023-38. [Ref.ID 100911]
11. Cita con resumen
Anónimo. FDA approves new indications for canakinumab. DIA Daily 2016;27 de septiembre:3. [Ref.ID 100759]
12. Cita con resumen
Anónimo. FDA approves ustekinumab for adults with moderate to severe Crohn’s. DIA Daily 2016:2. [Ref.ID 100758]
13. Cita con resumen
Gottenberg J-E, Brocq O, Perdriger A, Lassoued S, Berthelot J-M, Wendiing D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B, Constantin AL, Mariette X, Morel J, Gilson M, Cormier G, Salmon JH, Rist S, Lioté F, Marotte H, Bonnet C, Marcelli C, Sellam J, Meyer O, Solau-Gervais E, Guis S, Ziza J-M, Zarnitsky C, Chary-Valckenaere I, Vittecoq O, Saraux A, Pers Y-M, Gayraud M, Bolla G, Glaudepierre P, Ardizzone M, Dernis E, Breban MA, Fain O, Balblanc J-C, Aberkane O, Vazel M, Back C, Candon S, Chatenoud L, Perrodeau E, Sibilia J, Ravaud P. Non-TNF-tarteged biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA 2016;316:1172-80. [Ref.ID 100753]
14. Cita con resumen
Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Glamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens E-P, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GBE. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 2016;375:422-34. [Ref.ID 100705]
15. Cita con resumen
Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, Munro R, McLaren J, McRorie E, Packham J, Buckley CD, Harvie J, Taylor P, Choy E, Pitzalis C, McInnes IB. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 2016;388:239-47. [Ref.ID 100631]
16. Cita con resumen
French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-a agents. Drug Saf 2016;39:199-208. [Ref.ID 100140]
18. Cita con resumen
Sansone AC, Mantarro S, Tuccori M, Ruggiero E, Montagnani S, Convertino I, Marino A, Fornai M, Antonioli L, Corona T, Garibaldi D, Blandizzi C. Safety profile of certolizumab pegol in patients with immune-mediated inflammatory disease: a systematic review and meta-analysis. Drug Saf 2015;38:869-88. [Ref.ID 99614]
19.Enlace a cita original Cita con resumen
Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, on behalf of the network of French pharmacovigilance centres, Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Duman MK, Meister R, Schaefer C. Pregnancy outcome after TNF-a inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727-39. [Ref.ID 99609]
20.
Boehncke W-H, Schön MP. Psoriasis. Lancet 2015;386:983-4. [Ref.ID 99530]
Seleccionar todas
 
 1 a 20 de 287 siguiente >>